BRTXBioRestorative Therapies, Inc.
This is the year BRTX has to prove it’s not just a ghost in the machine — it’s got to deliver. The next catalyst is the regulatory review resolution on 2026-09-25, which could either anchor the stock at $0.20 or send it soaring to $0.31 (bull) or sinking to $0.15 (bear). The lean is 55% bull, meaning the market is betting on a resolution that could unlock the next phase of this company’s journey. But the path is littered with tests, and each one is a chance to either prove the thesis or expose the cracks in the foundation.
The schedule
- Fri25Sep
Resolution of pending regulatory review, which could impact operations and market perception.
- Tue20Oct
Potential equity financing to support operations or expansion, with implications for capital structure.
- Wed11Nov
Earnings release for Q3 2026, with focus on financial results and guidance for the next quarter.
- Thu26Nov
Release of Phase 2 data for BRT, which could influence investor sentiment and valuation.
- Tue15Dec
Compliance with Nasdaq minimum bid price requirements, which could affect trading status.
- Sun14Feb
Earnings release for Q4 2026, with focus on financial results and guidance for the next quarter.
- Thu13May
Earnings release for Q1 2027, with focus on financial results and guidance for the next quarter.
